Side-by-side · Research reference
MGFvsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/55 cited
BHuman-MechanisticAUTO-DRAFTED12/40 cited
MGF
IGF-1Ec Splice Variant · Muscle-Specific
SQ · Research context only
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
MGF
Thymalin
Primary target
Satellite cells (Pax7+) in skeletal muscleMoore 2018
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Satellite cell proliferation, myoblast differentiation, muscle fiber repair
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Feedback intact?
—
—
Origin
Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016Vassilakos 2017
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
—
—
02Dosage Protocols
Parameter
MGF
Thymalin
Synthetic peptide
24-amino-acid E-domain sequence
Corresponds to human IGF-1Ec exons 4-6 region.
—
Rodent cardiac model
200 μg/kg via peptide-eluting microstructures
Post-MI injection; improved ejection fraction by 8 weeks.
—
Acute delivery (mouse MI)
Single bolus within 12 hrs post-infarctionShioura 2014
Delayed decompensation; no human protocol established.
—
Human evidence
None — no published clinical trials
All dosing extrapolated from animal models.
—
Detection in doping
Full-length MGF detected via LC-MS in illicit productsThevis 2014
WADA-prohibited since 2005; no therapeutic indication.
—
Frequency
—
Once daily during cycle
Lower / starter dose
—
2.5 mg / day
Duration
—
5–10 day cycles, 1–2× per year
Reconstitution
—
Saline or bacteriostatic water
Timing
—
Morning preferred
Half-life
—
Hours (estimated)
04Side Effects & Safety
Parameter
MGF
Thymalin
Human safety data
None — no clinical trials published
—
Theoretical IGF-1 axis risk
Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)
—
Tumor promotion
IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer
—
Antibody development
Unknown — no longitudinal human exposure data
—
Local injection reaction
Presumed similar to other peptides (erythema, induration) — no direct evidence
—
Dysregulated expression with age
Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018
—
Injection site reaction
—
Mild erythema at IM site
Allergic reaction
—
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Long-term safety
—
Limited Western data
Pregnancy / OB
—
Avoid
Absolute Contraindications
MGF
- ·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
- ·No established therapeutic use — investigational only
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
MGF
- ·Family history of IGF-1-axis malignancies
- ·Use outside research setting
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
MGF
Thymalin
1. No validated protocol
MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Synthetic peptide form
Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.
Intramuscular — deltoid or gluteal. Rotate sites.
3. Animal delivery models
Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015Shioura 2014
Morning preferred during cycle.
4. WADA prohibition
MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Research context only
Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.
23–25G, 25–38 mm IM needle.
06Stack Synergy
MGF
+ BPC-157
Multi-pathwayMGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.
- MGF
- No established dose
- BPC-157
- 250–500 mcg SQ near injury site
- Context
- Animal models only
- Primary benefit
- Theoretical multi-tissue repair (muscle + tendon/ligament)
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.
- MGF
- No established dose
- TB-500
- 2–5 mg SQ weekly
- Context
- Animal models only
- Primary benefit
- Satellite cell activation + enhanced migration/angiogenesis
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation